Peter Olagunju is currently serving as an Operating Partner at Catalio Capital Management and as a Member of the Board of Directors at March Biosciences. Peter previously held positions such as Chief Operating Officer at TCR² Therapeutics Inc. and Senior Vice President of Technical Operations at FerGene. With a background in Biology and Immunology, Peter has a strong track record in the cell and gene therapy industry, providing strategic support and operational leadership for various companies.
Current role